Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.","authors":"Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang","doi":"10.1007/s00432-025-06154-5","DOIUrl":"10.1007/s00432-025-06154-5","url":null,"abstract":"<p><strong>Aims: </strong>Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM) and obesity. This study intends to explore the potential effects and mechanism of Semaglutide on OSCC.</p><p><strong>Methods: </strong>The expression of GLP-1R in OSCC cells and tissues was evaluated by qRT-PCR, western blot and immunohistochemistry assays. Cell proliferation, invasion, migration and apoptosis abilities were determined by relevant experiments. Western blot was employed to verify the expression of relevant proteins and examine the effect of Semaglutide on the MAPK signaling pathway. The xenograft transplantation model of OSCC was established to examine the anti-cancer effects of Semaglutide in vivo and immunohistochemistry assays were performed on tumor tissues.</p><p><strong>Results: </strong>GLP-1R expression was elevated in OSCC cells and tissues as compared with that in normal. Semaglutide effectively inhibited the proliferation, migration and invasion of OSCC cells while concurrently promoting apoptosis. Moreover, Semaglutide specifically activated the P38 MAPK signaling pathway without significant influence on ERK1/2 or SAPK/JNK, and its pro-apoptotic effects in OSCC cells was related to P38 pathway activation. Animal experiments verified the inhibitory effect of Semaglutide on OSCC tumors in mice.</p><p><strong>Conclusions: </strong>Semaglutide exerts inhibitory actions on OSCC and may induce apoptosis in OSCC cells via the P38 MAPK signaling pathway. This study has significant implications for the treatment of patients with diabetes who are also afflicted by OSCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"103"},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer.","authors":"Laura Lawaczeck, Anna Rüdiger, Jörg Hennenlotter, Joël Hammes, Valentina Spingler, Simon Walz, Eva Erne, Igor Tsaur, Steffen Rausch","doi":"10.1007/s00432-025-06135-8","DOIUrl":"10.1007/s00432-025-06135-8","url":null,"abstract":"<p><strong>Purpose: </strong>Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care. This study examines clinical parameters that influence ITB recommendations, evaluates their adherence to guidelines, and assesses their impact on patient survival.</p><p><strong>Methods: </strong>In a retrospective analysis, data from 187 mCRPC patients discussed at an ITB in a tertiary care center in 2018 were evaluated. Patient- and disease-specific factors were correlated with adherence to National Comprehensive Cancer Network^® (NCCN^®) guidelines and overall survival (OS). The impact of clinical parameters on survival outcomes was assessed through univariate and multivariate analyses.</p><p><strong>Results: </strong>The median patient age was 72.8 years, with a median prostate-specific antigen (PSA) level of 65.0 ng/ml. Guideline-compliant recommendations were given in 42.9% of cases, while 57.1% received individualized recommendations. Clinical trial eligibility was noted in 24.8% of patients. Individualized ITB recommendations were associated with significantly longer OS (38.3 vs. 21.2 months, p = 0.03). Shorter OS correlated with renal impairment (p = 0.007), symptomatic metastases (p < 0.0001), and visceral metastases (p < 0.0001). Limitations include the retrospective design, lack of follow-up on therapy adherence, and absence of progression-free survival (PFS) data.</p><p><strong>Conclusion: </strong>ITB discussions improve survival in mCRPC patients, mainly due to personalized approaches and better access to clinical trials. Visceral and symptomatic metastases as well as renal impairment are risk factors for reduced OS, emphasizing the need for careful management of these high-risk patients. The results support the expanded use of ITB to improve mCRPC treatment outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"101"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The screening value of mammography for breast cancer: an overview of 28 systematic reviews with evidence mapping.","authors":"Jiyuan Shi, Jiang Li, Ya Gao, Wanqing Chen, Liang Zhao, Ni Li, Jinhui Tian, Zheng Li","doi":"10.1007/s00432-025-06122-z","DOIUrl":"10.1007/s00432-025-06122-z","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of mammography screening in reducing breast cancer mortality and the accuracy of various mammography techniques have been widely studied. However, the quality and findings of existing systematic reviews and meta-analyses require comprehensive evaluation.</p><p><strong>Methods: </strong>A systematic literature search was conducted in the Cochrane Library, EMBASE, and PubMed for systematic reviews published up until December 20, 2022. A total of 28 systematic reviews with meta-analyses were included. Two reviewers independently extracted data and assessed methodological quality using the Risk Of Bias In Systematic Reviews (ROBIS) tool.</p><p><strong>Results: </strong>Of the 28 systematic reviews included, only 17.9% were rated as low risk of bias. The pooled estimates for breast cancer mortality reduction due to mammography screening ranged from 0.51 (95% CI 0.46-0.55) to 1.04 (95% CI 0.84-1.27). The results were influenced by study design, age, and follow-up duration, with an overall trend indicating that mammography screening reduces breast cancer mortality. Sensitivity of mammography techniques ranged from 55 to 91%, and specificity from 84 to 97%. Digital breast tomosynthesis combined with synthetic contrast-enhanced spectral mammography, digital mammography, and film mammography demonstrated relatively high cancer detection rates and low false positives.</p><p><strong>Conclusion: </strong>Mammography screening appears effective in reducing breast cancer mortality. The accuracy of various mammography techniques is generally reliable, with certain combinations showing high detection rates. However, the methodological quality of most included reviews was at high risk of bias, indicating a need for higher-quality studies in the future.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"102"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study.","authors":"Katrin Schlack, Stefan Machtens, Thomas Kubin, Markus Ruhnke, Clemens Schulte, Anna Eisen, Ulrike Osowski, Silke Guenther, Mairead Kearney, Rainer Lipp, Stephan Schmitz","doi":"10.1007/s00432-025-06131-y","DOIUrl":"10.1007/s00432-025-06131-y","url":null,"abstract":"<p><strong>Purpose: </strong>CONVINCE is a retrospective medical chart review study that examined demographics, treatment patterns, and outcomes in patients who received first-line (1L) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany.</p><p><strong>Methods: </strong>Eligible patients were adults with confirmed la/mUC who received any systemic 1L anticancer treatment between January 1, 2019, and September 30, 2021, outside of a clinical trial. Patients were grouped by type of 1L treatment: platinum-based chemotherapy (PBC), immune checkpoint inhibitor (ICI), or other treatments. Follow-up was ≥ 6 months after end of PBC or start of ICI or other treatments. The primary objective was measurement of real-world progression-free survival (rwPFS).</p><p><strong>Results: </strong>Data were collected from 188 patients treated at 27 sites (hospitals or office-based practices). First-line treatment was PBC in 76.1% of patients, ICI in 19.1%, and other treatments in 4.8%. The most common PBC regimen was cisplatin + gemcitabine (72.7%), and the most common ICI was atezolizumab (44.4%); 4.2% of PBC-treated patients received avelumab 1L maintenance. In patients who received 1L PBC, ICI treatment, or other treatments, median (95% CI) rwPFS was 10.5 months (9.2-11.6), 12.6 months (8.9-22.9), and not evaluable; median (95% CI) real-world overall survival was 18.1 months (16.5-19.0), 15.9 months (11.1-24.5), and not evaluable; and objective response rates were 56.6%, 60.0%, and 83.3%, including complete response in 14.0%, 20.0%, and 0%, respectively.</p><p><strong>Conclusion: </strong>PBC was the most common 1L treatment in patients with la/mUC in Germany, consistent with treatment guidelines. Future studies are needed to assess outcomes with newer treatments.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"100"},"PeriodicalIF":2.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.","authors":"Yuming Zheng, Fen Xue, Dan Ou, Xiaoshuang Niu, Chaosu Hu, Xiayun He","doi":"10.1007/s00432-025-06145-6","DOIUrl":"10.1007/s00432-025-06145-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to evaluate the efficacy and toxicity of the two induction chemotherapy (IC) regimens (TPF: docetaxel, cisplatin and 5-fluorouracil, and PF: cisplatin and 5-fluorouracil) combined with radiotherapy in young and middle aged patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 329 cases with stage III-IVA nasopharyngeal carcinoma from September 2005 to February 2017. Of the 329 cases, 253 cases underwent TPF (docetaxel: 60 mg/m² on day 1, cisplatin: 25 mg/m² on days 1-3, 5-fluorouracil: 500 mg/m² on days 1-5, intravenous 120-h infusion), while 76 cases received the PF regimen (cisplatin: 25 mg/m² on days 1-3, 5-fluorouracil: 500 mg/m² on days 1-5, intravenous 120-h infusion) every 3 weeks. Radiotherapy was administered after IC with or without concurrent chemotherapy. The survival rates were assessed by Kaplan-Meier analysis, and the survival curves were compared using a log‑rank test.</p><p><strong>Results: </strong>The 5-year and 8-year overall survival (OS) rates of the PF group and TPF group were 80.1% and 72.1%, 87.3% and 78.4% respectively (p = 0.405). There were no statistical differences in regional recurrence-free survival (RRFS) and distant metastasis-free survival (DMFS) rates between PF and TPF groups(p = 0.585 and 0.500, respectively).The 5-year and 8-year estimated local recurrence free survival (LRFS) rates for patients in PF and TPF group were 91.1% and 78.0%, 96.2% and 93.7%, respectively (p = 0.026). Moreover, The OS, LRFS, RRFS and DMFS rates were comparable between the non CCRT or CCRT subgroup (p = 0.542, 0.319, 0.070, 0.986, respectively). Compared with PF group, the TPF group significantly increased the occurrence of grade 3 or 4 neutropenia and leukopenia (p < 0.001).</p><p><strong>Conclusion: </strong>PF and TPF followed by radiotherapy with or without concurrent chemotherapy performed encouraging anti-tumor effects in LA-NPC, there was no statistical significance in 5-year and 8-year OS, RRFS, and DMFS rates between two chemotherapy regimens. Compared with PF, TPF induction chemotherapy achieved more satisfactory LRFS rate in LA-NPC with acceptable toxicity.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"99"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA LINC01128 promotes prostate cancer cell proliferation, metastasis, and epithelial-mesenchymal transition by modulating miR-27b-3p.","authors":"Yuhui Zhao, Zhihang Zhang, Yi Zheng, Huiming Bai, Xiaotong Wu, Yantao Yang, Junfeng Zhang, Chao Yu","doi":"10.1007/s00432-025-06153-6","DOIUrl":"10.1007/s00432-025-06153-6","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is a prevalent malignancy within the male reproductive system that poses a significant threat to patients' lives. The function of long non-coding RNA LINC01128 in PCa progression remains to be elucidated.</p><p><strong>Objective: </strong>The objective was to evaluate the significance of LINC01128 in PCa and to elucidate the underlying mechanisms, thereby identifying a potential target for PCa treatment.</p><p><strong>Methods: </strong>The clinical significance of LINC01128 in PCa was investigated by bioinformatics methods and data analysis. The expression of LINC01128 was quantified using real-time quantitative PCR. The impact of LINC01128 on PCa cell viability and metastasis was evaluated through Cell Counting Kit-8 and Transwell assays. The expression of epithelial-mesenchymal transition markers was analyzed by Western blot analysis. Bioinformatics methods and dual-luciferase reporter assay were employed to explore the mechanisms underlying the role of LINC01128 in PCa progression.</p><p><strong>Results: </strong>LINC01128 demonstrated significant upregulation in PCa and exhibited a strong correlation with tumor-node-metastasis (TNM) stage, Gleason score, and lymph node metastasis. The upregulation of LINC01128 was found to be linked to a poorer prognosis for PCa. In PCa cells, silencing LINC01128 resulted in the suppression of cell proliferation, migration, and invasion. Furthermore, the knockdown of LINC01128 enhanced the expression of E-cadherin while concurrently repressing the expression of N-cadherin and Vimentin. Mechanistically, the negative regulation of miR-27b-3p by LINC01128 mediated the role of LINC01128 in PCa progression.</p><p><strong>Conclusions: </strong>In PCa, high expression of LINC01128 may predict patients' unfavorable prognosis. LINC01128 promoted PCa cellular processes by negatively regulating miR-27b-3p.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"98"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of prognosis and related influencing factors of different surgical approaches for early cervical cancer.","authors":"Lingling Ou, Lulu He, Qiaowen Bu, Hengying Wu, Bin Wen, Xiping Luo, Xiaoshan Hong","doi":"10.1007/s00432-025-06139-4","DOIUrl":"10.1007/s00432-025-06139-4","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the 5-year survival rates of patients with early cervical cancer (CC) under different surgical approaches and to analyze the factors affecting the prognosis of these patients.</p><p><strong>Methods: </strong>A retrospective analysis and follow-up study were conducted on patients who underwent surgical treatment for early CC at Guangdong Women and Children Hospital between January 2005 and December 2017. Prognostic factors were analyzed using the Kaplan-Meier method and Cox regression model.</p><p><strong>Results: </strong>A total of 726 patients were included, with 347 in the open surgery group and 379 in the laparoscopy group. The proportion of deep stromal infiltration in the open group was significantly higher than in the laparoscopy group (228/347 vs. 194/379, respectively; P < 0.05). Similarly, the tumor diameter (< 4 cm) was significantly larger in the open group compared to the laparoscopy group (51/347 vs. 26/379, respectively; P < 0.05). There were no statistically significant differences between the two groups in terms of the number of pregnancies, number of deliveries, menopause, contraceptive methods, high-risk HPV infection, clinical stage, pathological type, degree of differentiation, parametrial invasion, or lymph node metastasis (P > 0.05). The mean follow-up period was 53.15 ± 15.33 months. The overall 5-year survival rate (OS) for all patients was 89.0%, while the disease-free survival rate (DFS) was 86.8%. The 5-year OS rates in the open and laparoscopy groups were 87.2% and 90.4%, respectively, while the 5-year DFS rates were 84.6% and 88.6%, respectively, with no statistically significant differences between the groups (P > 0.05). Multivariate analysis revealed that clinical stage, vascular invasion, and tumor diameter were independent risk factors affecting survival and prognosis in patients with CC. However, the surgical approach did not significantly influence prognosis.</p><p><strong>Conclusion: </strong>The 5-year overall survival rate of patients with early CC was 89.0%. Laparoscopic surgery did not adversely affect the prognosis of early CC patients. Both surgical approaches demonstrate favorable prospects for treating early CC. Prognosis in early CC is influenced by clinical stage, vascular invasion, and tumor diameter, rather than the surgical approach used.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"97"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CENPF as a prognostic marker of glioma: unraveling the molecular mechanisms.","authors":"Xiuyang Chen, Yiwei Wu, Yining Xing, Peng Zhong","doi":"10.1007/s00432-025-06144-7","DOIUrl":"10.1007/s00432-025-06144-7","url":null,"abstract":"<p><strong>Objective: </strong>Glioma is the dominant primary intracranial malignancy. The roles of CENPF and the CENPF - p53 axis in glioma remain elusive. This study uses bioinformatics and animal experiments to clarify the relationship between CENPF and p53 in glioma. CENPF affects spindle assembly and chromosomal segregation, while p53 is a tumor-suppressor gene. Their dysregulation may interact and impact glioma development. Our research aims to uncover the underlying molecular mechanisms, offering new perspectives for glioma diagnosis and treatment.</p><p><strong>Method: </strong>Gene expression data from the Gene Expression Omnibus (GEO) database ( http://www.ncbi.nlm.nih.gov/geo/ ) were retrieved, specifically datasets GSE50161, GSE104291, and GSE12249. Volcano plots were generated to visualize differentially expressed genes (DEGs), and intersecting DEGs were identified using Venn diagrams. Weighted gene co-expression network analysis (WGCNA) was employed to construct and analyze the protein-protein interaction (PPI) network. Additionally, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted. Gene set enrichment analysis (GSEA) was utilized for comprehensive GO and KEGG analyses of the entire genome. Comparative Toxicogenomics Database (CTD) analysis was performed, and TargetScan was used to identify miRNAs regulating central DEGs. An animal model of glioma was established and analyzed via Western blot.</p><p><strong>Result: </strong>A total of 501 differentially expressed genes (DEGs) were identified, from which eight significant modules were generated and ten core genes were extracted. These core genes exhibited differential expression patterns between glioma tumor and non-tumor samples. Expression analysis revealed that the ten core genes associated with glioma (CENPF, PBK, ASPM, KIF2C, KIF20A, CDC20, TOP2A, NUSAP1, TTK, KIF23) were significantly upregulated in tumor tissues (P < 0.05). They are primarily enriched in protein signal transduction, coated membrane structures, AP-type membrane coat adaptor complexes, and chloride channel activity. KEGG pathway analysis indicated that these target genes were mainly involved in nicotine addiction, arginine and proline metabolism, beta-alanine metabolism, and histidine metabolism. The mouse model confirmed that CENPF and CDK-1 were highly expressed in glioma tissues, while p53, p21, and Caspase9 were downregulated, leading to inhibition of the apoptosis pathway and exacerbation of glioma progression. Overexpression of CENPF further suppressed key molecules in the p53-mediated apoptosis pathway. Conversely, low expression of CENPF activated these key molecules, inducing apoptosis in glioma cells.</p><p><strong>Conclusions: </strong>CENPF exhibits elevated expression levels in glioma, potentially inhibiting cell apoptosis via the p53 signaling pathway, consequently contributing to the onset and progression of glioma.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"96"},"PeriodicalIF":2.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related disparities in outcomes of survival in biliary tract cancer patients.","authors":"Nadiye Sever, Emil Yunusov, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Abdussamet Çelebi, Selver Işık, İbrahim Vedat Bayoğlu, Osman Köstek, Murat Sarı","doi":"10.1007/s00432-025-06096-y","DOIUrl":"10.1007/s00432-025-06096-y","url":null,"abstract":"<p><strong>Introduction: </strong>Biliary tract cancer (BTC) is a rare and aggressive cancer with a poor prognosis. Despite treatment, overall survival is less than 12 months. It is a proven fact that women have better chemotherapy responses and survival than men in almost all cancer types. We believe that gender is one of the important factors affecting the prognosis of BTC. In this study, we aimed to investigate the effect of gender on prognosis in this type of cancer.</p><p><strong>Methods: </strong>This study was designed as a single-centre retrospective analysis of patients with BTC. All patients, regardless of operability, were included in the study. Prognostic factors were analysed using univariate and multivariate analysis.</p><p><strong>Results: </strong>A total of 100 patients (48% female) were included in the study. The median follow-up time was 72.2 months (95% CI 39.3-105.0), and the median OS was 9.5 months (95% CI 5.3-13.8) for all study patients. The 72-month survival rate was 13.4%. The observed survival rates at 10.4% for male patients and 15.7% for female patients demonstrate the importance of considering gender as a prognostic factor. A multivariate analysis indicated a significant association between female gender and longer overall survival, with an adjusted hazard ratio of 0.59 (95% CI 0.38-0.92, p = 0.02).</p><p><strong>Conclusion: </strong>It is clear that female gender is associated with a better response to chemotherapy and longer survival in BTCs. These findings should be taken into account in treatment selection and prognosis predictions. Further research may help elucidate the mechanisms underlying these sex differences and help develop more effective treatments.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"95"},"PeriodicalIF":2.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China.","authors":"Liyuan Wu, Wei Rao, Lei Guo, Fanshuang Zhang, Weihua Li, Jianming Ying","doi":"10.1007/s00432-025-06118-9","DOIUrl":"10.1007/s00432-025-06118-9","url":null,"abstract":"<p><strong>Purpose: </strong>The Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of KRAS across various cancer types.</p><p><strong>Methods: </strong>Using next-generation sequencing (NGS) technology and a panel of 520 genes, KRAS mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.</p><p><strong>Results: </strong>An analysis of 10,820 tumor samples found KRAS mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence of KRAS mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24%. KRAS G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while KRAS G12V mutation is predominant in uterine cancer, and KRAS G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and KRAS G13D/G12V mutations in colorectal cancer. KRAS G13D notably affected TMB in uterus cancer, while KRAS G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between KRAS G13D/G12V mutations and MSI-H in colorectal cancer.</p><p><strong>Conclusions: </strong>KRAS mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific KRAS mutations are associated with TMB and MSI in various cancer types.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"94"},"PeriodicalIF":2.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}